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Abstract
Background: Despite advances in cancer diagnosis and treatment have significantly improved survival rates, patients
post-treatment-related health needs are often not adequately addressed by current health services. The aim of the
Women’s Wellness after Cancer Program (WWACP), which is a digitised multimodal lifestyle intervention, is to enhance
health-related quality of life in women previously treated for blood, breast and gynaecological cancers.
Methods: A single-blinded, multi-centre randomized controlled trial recruited a total of 330 women within 24 months
of completion of chemotherapy (primary or adjuvant) and/or radiotherapy. Women were randomly assigned to either
usual care or intervention using computer-generated permuted-block randomisation. The intervention comprises an
evidence-based interactive iBook and journal, web interface, and virtual health consultations by an experienced cancer
nurse trained in the delivery of the WWACP. The 12 week intervention focuses on evidence-based health education
and health promotion after a cancer diagnosis. Components are drawn from the American Cancer Research Institute
and the World Cancer Research Fund Guidelines (2010), incorporating promotion of physical activity, good diet,
smoking cessation, reduction of alcohol intake, plus strategies for sleep and stress management. The program is based
on Bandura’s social cognitive theoretical framework. The primary outcome is health-related quality of life, as measured
by the Functional Assessment of Cancer Therapy-General (FACT-G). Secondary outcomes are menopausal symptoms as
assessed by Greene Climacteric Scale; physical activity elicited with the Physical Activity Questionnaire Short Form
(IPAQ-SF); sleep measured by the Pittsburgh Sleep Quality Index; habitual dietary intake monitored with the Food
Frequency Questionnaire (FFQ); alcohol intake and tobacco use measured by the Australian Health Survey and
anthropometric measures including height, weight and waist-to-hip ratio. All participants were assessed with these
measures at baseline (at the start of the intervention), 12 weeks (at completion of the intervention), and 24 months (to
determine the level of sustained behaviour change). Further, a simultaneous cost-effectiveness evaluation will consider
if the WWACP provides value for money and will be reported separately.
Discussion: Women treated for blood, breast and gynaecological cancers demonstrate increasingly good survival rates.
However, they experience residual health problems that are potentially modifiable through behavioural lifestyle
interventions such as the WWACP.
Trial registration: The protocol for this study was registered with the Australian and New Zealand Clinical Trials
Registry, Trial ID: ACTRN12614000800628, July 28, 2014.
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Background
While the overall incidence of female cancers is increas-
ing, advances in diagnosis and treatment have signifi-
cantly improved survival rates. In some cases, this has
transformed cancer from an often fatal condition to a
chronic and often curable disease (for example, early
breast malignancies) [1]. Although survival rates are im-
proving, survival can involve a number of treatment-
related health problems including ovarian failure [2],
weight gain [3], cognitive alterations [4], and fatigue [5].
For women after cancer, these physical and psychological
sequelae can be severe and frequently adversely affect
their quality of life [2].
Recent studies indicate that many survivorship-related
health problems can be modified through lifestyle prac-
tices such as good diet, greater physical activity, and par-
ticipation in screening programs, though cancer
survivors do not necessarily adopt these behaviours [6,
7]. According to two large American studies, few people
treated for cancer met recommendations for smoking
cessation, alcohol minimisation, physical activity, or fruit
and vegetable intake [6, 8]. Conversely, our pilot work
indicates that many cancer survivors are highly moti-
vated to protect their health and are more likely to take
up beneficial lifestyle and risk reduction strategies if they
are targeted towards the end of or soon after completion
of treatment [9, 10].
Australian health services and cancer support organi-
sations do not often provide structured health promo-
tion programs to support cancer survivors to minimise
lifestyle-related health risks once they have ceased active
treatment, despite the public and personal health bene-
fits that these would provide. While a range of survivor-
ship programs in recent years have recognised the
chronic nature of cancer, most are narrowly targeted on
specific symptoms and not based on sound chronic dis-
ease self-management principles and the management of
risk through lifestyle [11]. The need for support is par-
ticularly acute among rural and outer metropolitan sur-
vivors, who have restricted access to face-to-face
services due to cost, time, geographical, and other bar-
riers. Novel approaches to promote beneficial lifestyle
practices in women after cancer, such as the WWACP,
have the potential to improve quality of life and reduce
chronic disease risk.
The aim of this randomised controlled trial (RCT) is
to determine the efficacy and cost effectiveness of a
multimodal, digitised lifestyle intervention — The
Women’s Wellness after Cancer Program or WWACP.
The WWACP aims to enhance health-related quality of
life in women previously treated for breast, gynaeco-
logical, or blood cancers. The hypotheses are that, com-
pared to usual care, women undertaking the WWACP
intervention will:
1. Demonstrate higher scores of HRQoL irrespective of
their place of residence.
2. Be more likely to have a body mass index (BMI)
within recommended healthy weight range (e.g. BMI
20–25, waist circumference < 80 cm)
3. Show greater long term adherence to diet, exercise,
sleep, alcohol, and smoking recommendations.
4. Evaluate if the WWACP provides better value for
money than the current usual care approaches
(reported elsewhere).
Methods
This multi-centre, single-blinded, randomized controlled
12-week trial involved five hospitals (public and private) and
consumer groups serving women from metropolitan and
non-metropolitan areas throughout Australia. The study
was funded by a National Health and Medical Research
Council (NHMRC) Partnership Grant (APP1056856). It re-
ceived ethical approval from the relevant Institutional Re-
view Boards of participating sites before commencing the
trial. Details of the trial are further illustrated in Fig. 1.
Sampling and recruitment
The study population included women aged 18 and
treated for breast, blood or gynaecological cancer within
the previous 24 months. These cancers were chosen as
they comprise approximately 46% of all female cancers in
Australia in 2007 [1] and their treatment is associated with
numerous ongoing health complaints. These problems in-
clude menopausal symptoms, osteopenia and osteopor-
osis, obesity, diabetes, cognitive alterations, peripheral
neuropathy and cardiac health consequences. Good evi-
dence indicates that many of these comorbidities can be
prevented or mitigated by consistent engagement in
health promoting activities and weight reduction [10, 12–
15], which are the foci of this intervention.
Participants were recruited by clinicians from five hos-
pital sites: Princess Alexandra Hospital, Royal Brisbane
and Women’s Hospital, St John of God Murdoch Hospital,
Peter MacCallum Cancer Institute, and the Choices Can-
cer Support Program; and through newsletters, emails and
websites of three consumer groups (the National Breast
Cancer Foundations’ Register4, CanSpeak Queensland,
and the Breast Cancer Network of Australia).
Inclusion criteria included completion of chemotherapy
(primary or adjuvant) and/or radiotherapy within the pre-
vious 24 months for breast, blood, or gynaecological can-
cer; English proficiency; and access to an Apple computer
and or iPad (due to interactive book’s comparability). Par-
ticipants were excluded if they had metastatic or advanced
cancer, inoperable or active loco-regional disease, were on
maintenance chemotherapy for blood cancers.
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Randomisation
The RCT comprises two treatments (intervention vs
usual care) and three time points for data collection;
baseline (t0), 12 weeks (t1) and 24 weeks (t2). The pro-
cedure for random allocation occurred after baseline
data collection and was performed by a member of the
research team independent of recruitment or data col-
lection. Permuted-block randomisation was used, with
the seed for the random number generator determined
by entering the number of treatments, and the numbers
of patients per specific block (i.e., with two treatment
groups and block sizes ranging from 2–8). The exact se-
quence was generated using algorithms [16, 17] available
at http://www.randomization.com.
Intervention
This multi-modal intervention was designed for delivery
via an e-health enabled platform. It comprises virtually-
delivered health professional consultations, an interactive
web interface (including podcasts), an interactive elec-
tronic book (iBook) which provides detailed intervention
instructions and supports participants to log relevant
health and lifestyle information into a journal.
The intervention targets health education and health
promotion incorporating Australian and international
recommendations for physical activity, diet, smoking
cessation and minimising alcohol intake; as well as strat-
egies to manage sleep and stress, menopausal symptoms,
and sexual problems over a 12 week period (see Tables 1
and 2 for further detail). The timing and application of
these strategies were tailored to meet patient’s individual
goals and functional capacities.
The iBook is structured around four chronological
steps: changing lifestyle; establishing healthy habits;
maintaining health for illness prevention; and becoming
independent. More specifically, Step 1 provides essential
information about a number of topics that form the
basis of the 12-week program. Participants receive prac-
tical advice about how to incorporate this information
into their lifestyle. Step 2 encourages participants to
apply their new lifestyle habits to the areas of healthy
weight, strong bones and hormonal change. Step 3 pre-
sents information about maintaining health for illness
prevention. Step 3 emphasises a healthy heart, diabetes
prevention, and cancer screening so that participants
can manage their treatment-related risks for chronic dis-
ease in a proactive way. Finally, Step 4 focusses on
Fig. 1 Flowchart for the WWACP study. Notes: a All participants completed a structured online questionnaire and virtual consultation with a research
assistant at baseline (t0), 12 weeks (t1) and 24 weeks (t2); b The control group received general information only; c The intervention group received
intervention materials and three virtual consultations with a breast cancer nurse at baseline (t0), 6 weeks (mid-intervention), and 12 weeks (t1)
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developing independence and sustaining healthy lifestyle
changes after the 12-week program.
The interactive website provided healthy living support
and home monitoring of measurable health indicators,
which are downloaded to the study team. The website
incorporates access to the downloadable iBook; educa-
tional podcasts and factsheets; a weekly exercise planner
and schedule; and a community message board.
Virtual consultations were provided by experienced
cancer nurses trained in the delivery of the WWACP, via
skype or FaceTime at weeks 0, 6, and 12 (see Table 3 for
further detail). These consultations included discussion
and health education about physical activity, healthy eat-
ing, stress, sleep menopause and sexuality after cancer
and strategies to promote intervention adherence. The
women had v physical and psychological capabilities, the
nurses therefore worked with them to set realistic goals
within the woman’s capacity.
Standard care
Participants allocated to the standard care group re-
ceived general information from their usual health pro-
fessionals during clinic visits about the management of
all symptoms, including general advice about exercise,
diet, tobacco and alcohol abstinence, plus information
Table 1 WWACP Intervention Content and Delivery Strategies
Week Delivery Strategies Content
1 Virtual consultation
delivered by specialist
cancer nurse
Physical activity, and healthy
eating messages; goal setting;
education; motivational
interviewing; development of
tailored health education and
individualised plan and goals.
Observational weight, and
self-measured height, waist/hip
circumference measures
2 Phone coaching, Journal,
Book, health education
material/website
Review plan and goals; develop
a personal action plan; identify
barriers; self-monitoring
3 Phone coaching, Journal,
Book, and website
Relapse prevention; coaching,
feedback, motivational
interviewing and self-monitoring.
4,12 Journal/website/SMS/e-mail Mobile phone text message
every week based on program
messages; news update every
four weeks; motivational
messages sent as women
reach set goals.
6,12 Virtual RN consultation Review of plan and goals;
coaching; relapse prevention;
motivational interviewing;
biophysical measurements.
Observational weight and
self-measured height, waist/hip
circumference measures
1,12, 24 Data collection by RA Observational, weight, waist/hip
circumference measures and
on-line questionnaire
Table 2 The Women’s Wellness after Cancer Program targeted
behaviours [40]
Targeted Behaviours Rationale/Evidence
Body Fatness: Be as lean as
possible within the normal
weight range, avoid weight
gain and increases in waist
circumference
Maintenance of a healthy weight
may be one of the most important
ways to protect against cancer
recurrence and other common
chronic diseases, including
hypertension, stroke, type 2 diabetes
and coronary heart disease [40]
Physical Activity: Be moderately
physically active, equivalent to
brisk walking, for at least 30 min
per day; As fitness improves,
aim for 60 min or more of
moderate, or for 30 min or more
of vigorous, physical activity
every day
Physical activity of longer duration
or greater intensity is more
beneficial; All forms of physical
activity protect against some
cancers, as well as against weight
gain, overweight, and obesity [40]
Diet: Eat mostly foods of plant
origin; limit consumption of
energy-dense foods; avoid
sugary drinks, limit intake of
red meat and avoid
processed meat
An integrative approach to the
evidence shows that most diets
that are protective against cancer
are mainly made up from foods of
plant origin; Consumption of
energy-dense foods and sugary
drinks contributes to obesity;
An integrated approach to the
evidence also shows that many
foods of animal origin are nourishing
and healthy if consumed in modest
amounts.
Alcohol: If alcoholic drinks
are consumed limit
consumption to no more
than one drink per day
The evidence on cancer justifies a
recommendation not to drink
alcoholic drinks. Other evidence
shows that modest amounts of
alcoholic drinks are likely to reduce
the risk of coronary heart disease [40]
Table 3 Consultation nurse delivery strategies and content
Week Delivery strategies Content
1 Virtual consultation delivered
by specialist cancer nurse:
Phone coaching, iBook,
health education material,
website and email
Introduction to website and
IBook. Physical activity, and
healthy eating messages;
goal setting; education;
motivational interviewing;
development of tailored health
education and individualized
plan and goals. Discuss healthy
weight measures and associated
risk factors i.e. BMI, waist/hip
ratio. Discuss menopause,
stress, sleep and other concerns.
Discuss appropriate screening.
3 (email) Email to check progress
6 Review plan and goals;
Discuss personal action plan;
identify barriers, self-monitoring
12 Reviews of plan and goals;
coaching; relapse prevention;
motivational interviewing;
biophysical measurements;
review observational weight
and self-measured height,
waist/hip circumference
measures.
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about support services. No specific or individual advice
was provided, as per usual practice.
Quality assurance
This study was conducted in accordance with the Inter-
national Conference of Harmonisation Guideline E6 –
Good Clinical Practice (ICH-GCP) recommendations for
clinical trials. Regular auditing of the adequacy and ef-
fectiveness of internal controls was undertaken0of risk
management and compliance frameworks by the inde-
pendent Clinical Trial Manager of the lead university.
To ensure the reliability of the anthropometrical mea-
sures and survey data collected by research assistants
(RAs), standard operating procedures were developed.
RAs also received a one-day training workshop prior to
commencing data collection and were audited periodic-
ally by the research manager.
The fidelity of the nurse consultations was enhanced
by ensuring that the trial nurses, who were experienced
in cancer care, were also trained in the use of the inter-
vention. Nurses received a self-directed protocol manual
and DVD, and participated in a full day skills develop-
ment session delivered by members of the research
team. To ensure adherence to study protocols, peer re-
view of virtual consultations was conducted by the clin-
ical manager and nurses also completed a checklist at
the end of each session to indicate the strategies used.
Measurements
Primary and secondary endpoints were measured at
three time points (baseline, post-intervention or 12, and
24 weeks after the end of the trial) through a self-
completed electronic survey or through RA data collec-
tion. Table 4 outlines the timing and mode of adminis-
tration for each instrument. Data collectors were blinded
to the group allocation of the participants.
Primary endpoint
The primary outcome measure was health-related quality
of life as determined by the Functional Assessment of
Cancer Therapy-General (FACT-G) [18], a 28-item instru-
ment used extensively to assess satisfaction with the treat-
ment relationship, physical, functional, social, and
emotional well-being, and overall quality of life (QoL).
Psychometric testing has shown good internal consistency
(Cronbach alphas: physical sub-scale, 0.82; functional sub-
scale, 0.80; social sub-scale, 0.69; emotional sub-scale,
0.72; and total score, 0.89), test-retest reliability (0.88, 0.84,
0.82, 0.82, 0.92 respectively), and validity [18].
There is little consensus over the minimal clinically
important difference (MCID) in health-related quality of
life scores that constitutes a meaningful difference for
participants (either beneficial or harmful), with MCID in
the FACT-G total scores ranging from 4–8 points [19–
21]. Using a distribution-based approach, a 6 point or
greater improvement in the FACT-G total scores (be-
tween t0 and t1) was considered a minimal clinically im-
portant change for women in the study [19–22].
Secondary endpoints
Changes in several secondary outcome measures were
also assessed with the following instruments:
1. Menopausal symptoms were measured using the
standard Greene Climacteric Scale© [23], a 21-item
scale that assesses self-reported vasomotor symp-
toms, somatic symptoms, psychological symptoms
(anxiety and depression), and sexual function [23].
This scale has consistently demonstrated good psy-
chometric properties and has been used in
population-based and clinical samples in a variety of
locales [23, 24].
2. Anthropometric measures were collected by RAs
using standard protocols for the measurement of
height and weight (from which BMI was derived),
waist-to-hip ratio, and percentage of body fat. BMI
was grouped according to the WHO International
Classification of adult weight [25] (i.e., <18.5 being
underweight, between 18.5 - 24.9 being in the nor-
mal weight range, and ≥ 30 being obese).
3. Alcohol and tobacco use was assessed using several
questions from the Australian Health Survey, a
population–based survey designed that assesses the
past and current patterns of consumption among
the Australian population aged 18 and over [26].
4. Habitual dietary intake (including greater detail of
alcohol consumption) was monitored through the
Food Frequency Questionnaire (FFQ) [27, 28]. The
FFQ covers dietary intake of cereal foods, sweets and
snacks, dairy products, meats and fish, fruit,
vegetables, and alcoholic beverages [27, 28] and is
one of few dietary intake measures that minimises
day-to-day variability by assessing usual dietary in-
take in the past 12-months.
5. Physical activity was measured using the validated
International Physical Activity Questionnaire Short
Form (IPAQ-SF) [29]. The short version of this
instrument is recommended for use in national and
regional surveillance systems [30]. It assesses three
types of activity (walking, moderate-intensity activ-
ities and vigorous-intensity activities), which are all
targeted behaviours within the intervention.
6. Sleep activity and quality were measured using the
Pittsburgh Sleep Quality Index (PSQI), a 19-item
self-report instrument with well-established reliabil-
ity and validity [27]. The PSQI includes seven sub-
scales (subjective sleep quality, sleep latency, sleep
duration, habitual sleep efficiency, sleep disturbances,
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use of sleeping medication, and daytime dysfunction)
and an overall summary score and has demonstrated
utility in both clinical and research settings [27].
Data analysis
Sample size calculations
A priori power analysis [28, 31] determined the mini-
mum sample size required for each group is 268, with a
total sample size of 536 (calculation based on: standar-
dised mean difference (SMD) = 0.65, 90% power, 95%
confidence interval; 25% non-response). However, delays
in ethical approval across sites and slower than antici-
pated recruitment meant the initial calculation were re-
vised. Thus A posteriori power analysis were performed
and revealed that 250 participants (125 per group) were
required to detect a standardised mean difference
(SMD) of 0.6 or greater [32, 33] in the primary outcome
measure (FACT-G total). Calculations were based on
achieving 80% power, with a type I error of 5% (two-
tailed) to detect a 5.7 change in the standard deviation
of the FACT-G total (M = 76.2, SD = 14.3 from pilot
study [10]), and 25% non-adherence (10% lost to follow-
up and 15% non-response).
Primary analysis
All statistical data will be analysed using Statistical Package
for the Social Sciences (SPSS)® version 23 [34] and STATA
13 [35] statistical packages in adherence with the CON-
SORT reporting guidelines [36]. Baseline measures and par-
ticipant characteristics will be initially compared to assess
for imbalances and differences between groups while the
primary endpoint (HRQoL) will examine within- and
between-group differences in FACT-G scores over the
study period. Logistic regression models will examine pre-
dictors of quality of life (including baseline quality of life),
age and sociodemographic variables. This includes explor-
ing the rurality of the women according to the classifica-
tions of highly accessible, accessible, moderately accessible,
remote, and very remote location suggested by the Accessi-
bility/Remoteness Index of Australia (ARIA) [37]. Linear
Table 4 Outcome measures, instruments, modes of administration, and time points of the study
Measures Instruments Time point Mode of administration
t0 (baseline) t1 (12 weeks) t2 (24 weeks) Online survey RA data collection
Background information
Socio-demographics
Medical and surgical history X Assesses changes in medical/surgical history,
and medications since baseline
X
Cancer diagnosis and treatment X X
Medications X X
Subjective health indicators
HRQoL FACT G [18] X X X X
SF – 36 [41] X X X X
Depression CES – D [42]
Anxiety Zung SAS [43]
Sexuality
Sexual function FSFI [44] X X X X
Exercise self-efficacy ESE [45] X X X X
Dietary self-efficacy DSE [45] X X X X
Menopausal symptoms
Menopausal symptoms GCS [23] X X X X
Modifiable lifestyle factors
Diet FFQ [46, 47] X X X X
Physical Activity IPAQ [48]
Sleep PSQI [27]
Waist and hip circumference X X X X
Cost effectiveness evaluation
Calendar of costs incurred X X X X
FACT G Functional Assessment of Cancer Therapy – General, SF – 36, Short Form 36, CES – D, Center for Epidemiologic Studies Depression Scale, Zung SAS Zung
self-rating anxiety scale, FSFI Female Sexual Function Index, ESE Exercise Self-Efficacy, DSE Dietary Self-Efficacy, GCS Greene Climacteric Scale; FFQ Food Frequency
Questionnaire, IPAQ International Physical Activity Questionnaire, PSQI Pittsburgh sleep quality index
Anderson et al. BMC Cancer  (2017) 17:98 Page 6 of 8
mixed models (LMM) will analyse between-group changes
and changes over time in secondary outcomes such as en-
ergy, macronutrient and micronutrient intake, body fatness,
menopausal symptoms, levels of physical activity, alcohol,
and smoking.
Discussion
Recent research indicates that women diagnosed with
blood, breast, and gynaecological cancers have a distinct set
of health needs after treatment. For example, among breast
cancer survivors menopausal symptoms, infertility, fatigue,
lymphedema, and osteoporosis can persist after treatment
and are likely to have a significant and negative affect on
ongoing health and wellness [38]. In many instances, the
health system does not adequately address these health is-
sues and is struggling to support the increasing number of
cancer survivors in the population who subsequently de-
velop treatment-related chronic diseases [39].
This study seeks to trial the effectiveness of a digitised,
multimodal lifestyle intervention for the management of
treatment-induced late health effects in women after
cancer. We used an e-health enabled platform to reduce
accessibility issues associated with cost, time, geograph-
ical, and other constraints.
Close-out will occur November 2016, at which time data
will be prepared for the longitudinal data analysis. The
findings from this study will contribute to evidence-based
information about the utility and benefits of structured
health promotion activities for women after cancer.
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